Association Between Elevated Fibrosis Markers and Heart Failure in the Elderly
Authors:
- Eddy BaraschEBEddy Barasch
- John S. GottdienerJGJohn S. Gottdiener
- Gerard AurigemmaGAGerard Aurigemma
- Dalane W. KitzmanDKDalane W. Kitzman
- Jing HanJHJing Han
- Willem J. KopWKWillem J. Kop
- Russell P. TracyRTRussell P. Tracy
- 1 July 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 2 (4) , 303-310
Abstract
Myocardial fibrosis reflects excess collagen deposition in the extracellular left ventricular matrix, which has been associated with heart failure (HF). No studies have addressed the relation between fibrosis biomarkers and HF in the elderly. Serum fibrosis markers were measured in 880 participants of the Cardiovascular Health Study (mean age 77+/-6 years, 48% women). Participants with systolic HF (n=131, left ventricular ejection fraction or =55%) were compared with controls (280 with cardiovascular risk factors, and 279 healthy individuals) using a nested case-control design. Fibrosis markers included carboxyl-terminal peptide of procollagen type I, carboxyl-terminal telopeptide of collagen type I, and amino-terminal peptide of procollagen type III. Echocardiography was used to document systolic and diastolic function parameters. Analysis of variance and logistic regression analysis (per tertile odds ratios [OR]), adjusted by age, gender, race, hypertension, atrial fibrillation, coronary heart disease, baseline serum glucose, serum cystatin C, serum creatinine, C-reactive protein, any angiotensin-converting enzyme inhibitor, spironolactone or any diuretic, NT-proBNP, and total bone mineral density were performed. Systolic HF was associated with significantly elevated carboxyl-terminal telopeptide of collagen type I (OR=2.6; 95% CI=1.2 to 5.7) and amino-terminal peptide of procollagen type III (OR=3.3; 95% CI=1.6 to 5.8), when adjusting for covariates. Associations of diastolic HF were significant for carboxyl-terminal telopeptide of collagen type I (OR=3.9; 95% CI=1.9 to 8.3) and amino-terminal peptide of procollagen type III (OR=2.7; 95% CI=1.4 to 5.4). HF was not associated with elevated carboxyl-terminal peptide of procollagen type I (P>0.10), and fibrosis markers did not significantly differ between HF with diastolic versus those with systolic dysfunction (P>0.10) whereas NT-proBNP mean values were higher in systolic heart failure than in diastolic heart failure (P<0.0001). Fibrosis markers are significantly elevated in elderly individuals with diastolic or systolic HF. These associations remained significant when adjusting for covariates relevant to the aging process.Keywords
This publication has 30 references indexed in Scilit:
- Biomarkers of bone health and osteoporosis riskProceedings of the Nutrition Society, 2008
- Cytokines, interstitial collagen and ventricular remodelling in dilated cardiomyopathyInternational Journal of Cardiology, 2008
- Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the communityAmerican Heart Journal, 2007
- From Inflammation to Fibrosis: A Stiff Stretch of HighwayHypertension, 2004
- Age related changes of the collagen network of the human heartMechanisms of Ageing and Development, 2001
- Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosisThe American Journal of Cardiology, 1995
- Natriuretic Peptides Inhibit DNA Synthesis in Cardiac FibroblastsHypertension, 1995
- The cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertension and heart failureCurrent Opinion in Cardiology, 1994
- Review of Calcium in Muscle Contraction, Cellular, and Molecular Physiology, by J. C. Rüegg.Journal of Molecular and Cellular Cardiology, 1994
- The cardiovascular health study: Design and rationaleAnnals of Epidemiology, 1991